论文信息 - Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study). - 字舞流文

Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).

Not available.

P. Feugier | L. Fornecker | V. Eclache | A. Delmer | V. Leblond | I. Radford‐Weiss | K. Maloum | C. Settegrana | E. Chapiro | F. Nguyen‐Khac | L. Baseggio | S. Struski | E. Ferrant | D. Ghez | L. Sutton | C. Lefebvre | A. Brion | A. Michallet | J. Lesesve | C. Tomowiak | Louis Pérol | D. Roos-Weil | S. Ivanoff | Justine Siavellis | C. Algrin

[1] A. Rosenwald,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[2] L. Staudt,et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[3] C. Zent,et al. Initial treatment of B‐cell prolymphocytic leukemia with ibrutinib , 2020, American journal of hematology.

[4] O. Bernard,et al. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. , 2019, Blood.

[5] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[6] M. Damlaj,et al. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations , 2018, Leukemia & lymphoma.

[7] Philipp W. Raess,et al. Ibrutinib is an effective treatment for B‐cell prolymphocytic leukaemia , 2017, British journal of haematology.

[8] A. Schuh,et al. Idelalisib‐Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia , 2017, British journal of haematology.

[9] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[10] C. Dearden. Management of prolymphocytic leukemia. , 2015, Hematology. American Society of Hematology. Education Program.

[11] G. Flandrin,et al. A Multicentric Study of 41 Cases of B-Prolymphocytic Leukemia: Two Evolutive Forms: The Groupe Français d'Hématologie Cellulaire , 2001, Leukemia & lymphoma.

[12] T. Crook,et al. p53 abnormalities in B-cell prolymphocytic leukemia. , 1997, Blood.